Skip to content

Prospective Feasibility study to evaluate safety and efficacy of Ultrasound Cyclo Plasty in Chinese Open Angle Glaucoma and Angle-closure Glaucoma patients with vision

Prospective Feasibility study to evaluate safety and efficacy of Ultrasound Cyclo Plasty in Chinese Open Angle Glaucoma and Angle-closure Glaucoma patients with vision

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900022880
Enrollment
Unknown
Registered
2019-04-29
Start date
2019-05-01
Completion date
Unknown
Last updated
2019-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Interventions

1:UCP treate

Sponsors

Chongqing Aier Maige Eye Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1 Glaucoma patients whose IOP is not well controlled with glaucoma medication; 2 IOP = 21 mmHg; 3 Visual acuity = 0.1; 4 Visualfield MD 18 years and < 85 years; 8 Able and willing to sign the informed consent form and complete postoperative follow-up requirements.

Exclusion criteria

Exclusion criteria: 1 For both eye: Ocular infection within 14 days prior to the procedure of Ultrasound Cyclo Plasty. 2 For study eye: (1) History of cyclo-destructive procedures (cryotherapy, diode laser cyclo-destruction, and endo-photo-coagulation); (2) History of ciliary body surgery; (3) History of ocular or retrobulbar tumor; (4) History of vitrectomy; (5) Aphakia; (6) Eye with implantation of glaucoma drainage device; (7) Neovascular glaucoma with/or without hyphema and/or vitreous haemorrhage; (8) Structure abnormalities in anterior segment which lead to excessive scleral expansion or change of ciliary body location; (9) Ocular disease other than glaucoma that may affect assessment of IOP (choroidal hemorrhage or detachment, lens subluxation, thyroid ophthalmopathy, and retinal detachment). 3 General: (1) Any other systemic illness as per investigators discretion which will jeopardize patients participation in the study. (2) High-risk population: systemic anxiety disorder, inability to move, etc.. (3) Women currently pregnant. (4) Participation in any other clinical trial (drug or device study) within 30 days prior to Screening.

Design outcomes

Primary

MeasureTime frame
IOP;VA;

Countries

China

Contacts

Public ContactZhou Xiaohong

Chongqing Aier Maige Eye Hospital

270037310@qq.com+86 18883920840

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026